Gribero (Dabigatran Etexilate Mesilate)

Gribero is indicated for several clot‑related conditions where anticoagulation is required.

• Prevention of stroke and systemic embolism in adults with non‑valvular atrial fibrillation.
• Treatment of acute deep vein thrombosis (DVT) to reduce clot extension.
• Prevention of recurrent DVT following initial therapy.
• Treatment of pulmonary embolism (PE) and prevention of its recurrence.
• Prophylaxis of venous thromboembolism after orthopedic surgery when indicated.

The safety profile of Gribero includes both frequently observed and less common adverse reactions.

Common

• Minor gastrointestinal upset such as nausea, dyspepsia, or abdominal discomfort.
• Mild bruising or bleeding from cuts, gums, or minor injuries.
• Headache or dizziness that does not interfere with daily activities.
• Low platelet count (thrombocytopenia) detected in routine blood tests.

Serious

• Severe or uncontrolled bleeding, including gastrointestinal or intracranial hemorrhage.
• Allergic reactions presenting as rash, itching, swelling, or difficulty breathing.
• Elevated liver enzymes indicating possible hepatic injury.
• Acute kidney injury or significant rise in serum creatinine.

Before prescribing Gribero, clinicians should evaluate patient-specific factors and monitor for potential risks.

• Assess renal function; dose adjustment may be required in moderate to severe impairment.
• Review history of bleeding disorders, gastrointestinal ulcers, or recent major surgery.
• Use cautiously in patients aged 75 years or older due to higher bleeding risk.
• Avoid in individuals with known hypersensitivity to dabigatran or its excipients.
• Counsel patients on the importance of adherence to avoid sub‑therapeutic exposure.
• Discontinue before invasive procedures and follow recommended interruption intervals.

Gribero may interact with other medicines that affect hemostasis or drug metabolism, requiring dose adjustments or monitoring.

Avoid

• Concomitant use with other anticoagulants (e.g., warfarin, heparin) or antiplatelet agents (e.g., clopidogrel) due to additive bleeding risk.
• Strong P‑glycoprotein (P‑gp) inhibitors such as ketoconazole, itraconazole, or ritonavir, which can increase dabigatran exposure.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) at high doses, which may exacerbate gastrointestinal bleeding.

Use with caution

• Moderate P‑gp inhibitors (e.g., amiodarone, verapamil) that may modestly raise dabigatran levels.
• Dual antiplatelet therapy when the clinical benefit outweighs bleeding risk.
• Herbal supplements like ginkgo biloba or garlic that possess antithrombotic properties.